Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023 06:00 ET
|
Immuron Limited
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
July 25, 2023 06:00 ET
|
Immuron Limited
Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron Business Update - Ateria Health launches Juvia™ in Australia
July 11, 2023 06:00 ET
|
Immuron Limited
Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in AustraliaNew clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to...
Immuron Initiates Recruitment of Travelan® Clinical Study
May 30, 2023 06:00 ET
|
Immuron Limited
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
May 08, 2023 06:00 ET
|
Immuron Limited
Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily...
Immuron Submits IND Application To FDA for Travelan
December 05, 2022 06:00 ET
|
Immuron Limited
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
October 04, 2022 06:00 ET
|
Immuron Limited
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
November 15, 2021 06:00 ET
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
US DoD Naval Medical Research Center Clinical Update
November 10, 2021 06:00 ET
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
Immuron Travelers’ Diarrhea Market Update
October 12, 2020 06:00 ET
|
Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...